Background and aims To date, the association between special AT-rich sequence-binding protein 1 (SATB1) and colorectal cancer (CRC) has not been reported. This study was aimed at investigating the expression and potential role of SATB1 in human rectal cancers.
Introduction
Colorectal cancer (CRC) is one of the most common gastrointestinal tumors and the second leading cause of Electronic supplementary material The online version of this article (doi:10.1007/s00384-011-1302-9) contains supplementary material, which is available to authorized users.
cancer-associated deaths in the world. The incidence of CRC in China is lower than that in the Western world but has been increasing in recent years [1] . Although advanced methods of diagnosis and treatment have been employed over the last few decades, the overall survival rate of patients with CRC has not improved markedly. Distant metastasis is the most common cause of death in CRC patients, although little is known about the exact mechanisms underlying the metastasis of this type of cancer. Therefore, identifying key regulators and their functions in colorectal metastasis will be vitally important for the future development of effective interventions.
Special AT-rich sequence-binding protein 1 (SATB1) is a thymocyte-specific matrix association region (MAR)-binding protein that links specific DNA elements to its cage-like network [2] . It facilitates formation of an open chromatin structure and participates in the regulation of hundreds of genes. In recent years, a number of studies have suggested that it plays major roles in T-cell development, early erythroid differentiation, homeostasis and response to physiological stimuli [3] [4] [5] [6] . In addition to discoveries of these physiological roles, SATB1 has recently attracted considerable attention due to its high expression in various types of malignant tumors, such as breast cancer, gastric cancer and laryngeal cancer, which suggest a crucial role in promoting tumor invasion and metastasis [7] [8] [9] [10] . A recent study showed that the expression of SATB2, a closely related homolog of SATB1, is associated with metastasis and poor prognosis in CRC [11] . However, the relationship between SATB1 and CRC has not been reported.
In this study, we investigated the prevalence and clinicopathological implications of SATB1 expression in 93 patients with primary rectal cancer. Furthermore, by using quantitative real-time PCR (qRT-PCR) and Western blotting analysis, we confirmed the results in a panel of colon cancer cell lines. The results of this study indicate that SATB1 expression correlates with the invasiveness of tumor cells and may be a new pathway marker for the progression of CRC.
Materials and methods

Tissue specimens
One hundred paired samples of rectal cancer and distant normal rectal tissues were obtained from 105 in-patients who underwent surgeries at the West China Hospital of Sichuan University (Sichuan, China) from February to November 2009. The patients received no chemotherapy or radiation before the operation. The rectal cancer and paired normal rectal tissues were allocated into the cancer and control groups, respectively. Parts of each sample were fixed in formalin and embedded in paraffin wax. Tumor histotype and grading were defined according to the recommendations of the World Health Organization for the histological typing of CRC. All cases were staged using the 7th edition of the Cancer Staging Manual of the American Joint Committee on Cancer (AJCC) [12] . Differentiation of low-grade tumors was good and moderate, while that of high grade tumors were poor and unspecified. Histopathological examinations were conducted by the Pathological Research Institution of West China Hospital. Carcinoma cells were observed in all cancer samples under an optical microscope. Informed consent was provided by all subjects, and approval was obtained from the Regional Ethics Committee. Of 105 cases, 12 were excluded because of tissue unavailability or incomplete medical records, resulting in a total of 93 eligible cases.
Cancer cell lines
Human colon carcinoma cell lines KM12C, KM12SM and KM12L4A were kindly provided by Isaiah Fidler (M.D. Anderson Cancer Center, Houston, TX, USA). The parental cell line KM12C was originally established from a primary Dukes B2 colon carcinoma. Cells from this cell line were repeatedly passaged in athymic mice by injection into the cecum and spleen, and two new cell lines, KM12SM and KM12L4A, were isolated with high metastatic potential. The cell lines were maintained in Eagle's MEM medium supplemented with 10% heat-inactivated fetal bovine serum, sodium pyruvate, vitamins and a cocktail of penicillin and streptomycin at 37°C in 5% carbon dioxide. Cells growing in the exponential phase were harvested at approximately 80% confluence. The HCT116 and SW480 cell lines obtained from our laboratory were used as controls and grown in standard culture conditions.
Primers and probes
The primers and probes designed for qRT-PCR were purchased from TNXK Biotechnology (Beijing, China). The probes for SATB1 and β-actin (reference gene) were 5′-FAM-CCAGCGTAACAGCTCGCACAAC-TAMRA-3′ and 5′-FAM-TCAACACCCCAGCCATGTACGT-TAMRA-3′, respectively. For SATB1, the forward primer was 5′-AAAT-GAAGCGTGCTAAAGT-3′, and the reverse primer was 5′-GTTCTCCCACAGGGTTCT-3′; while the forward and reverse primers for β-actin were 5′-AAGGCCAACCGCGA-GAA-3′ and 5′-CCTCGTAGATGGGCACA-3′, respectively.
RNA extraction and qRT-PCR
Total RNA was extracted from each tissue sample or 3×10 6 cells of each cell line, using TRIzol following the standard protocol. Reverse transcription was performed according to the manufacturer's instructions (TaKaRa Biotechnology, Japan). A 25-μl PCR reaction mix included: 3.0 μl dNTP (2.5 mM), 2.5 μl Mg 2+ (25 mM), 0.4 μl Taq polymerase (Fermentas, Lithuania), 2.5 μl 10× PCR reaction buffer (TaKaRa, Japan), 0.4 μl probe (10 μM), 0.4 μl PCR forward primer (10 μM), 0.4 μl PCR reverse primer (10 μM), 1 μl cDNA and 14.4 μl ddH 2 O. All PCR reactions were conducted by the two-step method on an iCycler iQ (Bio-Rad, USA) using the following conditions: denaturation at 95°C for 5 min, followed by 40 cycles of amplification and quantification at 95°C for 20 s, 49.0°C for 30 s and 72°C for 30 s. In addition, a no-template control (i.e., a negative control reaction including ddH 2 O instead of the DNA template) was analyzed for each run. All samples were amplified simultaneously in triplicate. The relative expression ratio (R) of a SATB1 gene was calculated based on PCR efficiency (E) and the C t deviation of an unknown sample versus the control: R ¼
, where ΔC t is the difference between the C t values of SATB1 and β-actin, and PCR efficiency (E) is approximately 2 by calculation. The ratio of more than 1 indicated that the mRNA expression of SATB1 in rectal cancer was up-regulated.
Immunohistochemical analysis
The tissue specimens were fixed in 4% paraformaldehyde, dehydrated and embedded in paraffin. The immunohistochemical analysis was performed on 4-μm-thick sections mounted onto poly-L-lysine coated glass slides. The sections were dewaxed in xylene and rehydrated in alcohol. The sections were heated in citrate buffer solution (pH 6.0) for 10 min in a microwave oven for antigen retrieval. The endogenous peroxidase activity was blocked by 3% hydrogen peroxide for 15 min. After rinsing three times in phosphate-buffered saline (PBS), the slides were treated with 10% normal goat serum at 37°C for 30 min. The sections were incubated overnight with the SATB1 antibody (diluted 1:250 in 5% goat serum in PBS; Epitomics) at 4°C. PBS was used as a negative control. After washing three times in PBS for 5 min each, the sections were incubated with biotinylated goat anti-mouse immunoglobulin (ZYMED) for 40 min and then with horseradish peroxidase-streptavidin complex (S-A/HRP; ZYMED) for 40 min, diluted as recommended by the manufacturer. After rinsing, 3,3′-diaminobenzidine (DAB; Abcam, Cambridge, MA, USA) was for colorimetric staining followed by hematoxylin counterstaining. Paraffin sections from a human breast carcinoma tissue were used as a positive control. For the negative control, the SATB1 antibody was substituted with PBS. To evaluate SATB1 levels, immunostained sections were scored with digital images obtained using the Olympus DD70 BX51 microscope (Olympus, Japan).
Evaluation of immunohistochemical staining and scoring
Patterns of staining, subcellular SATB1 localizations, staining intensities and percentages of SATB1 expressing cells were recorded. The staining patterns were evaluated using the immunoreactive score (IRS) proposed by Remmele and Stegner [14] , in which IRS=SI (staining intensity)×PP (percentage of positive cells). SI was determined as 0,
Western blotting
Proteins were extracted with RIPA lysis buffer (KeyGEN Biotech., China) and quantified using the Bradford method. After denaturation at 95°C for 5 min, equal amounts of proteins (20 μg) were loaded into each well of a 10% SDS-PAGE gel. After electrophoresis, the proteins were transferred to a polyvinylidene difluoride membrane at 100 V for 90 min (Bio-Rad, USA). The membrane was blocked with 5% skim milk for 1 h, followed by overnight incubation at 4°C with primary antibody, rabbit antihuman SATB1 (diluted 1:2,000; Epitomics, USA) or rabbit anti-human β-actin (diluted 1:1,000; Cell Signaling Technology, USA 
Results
Demographics
A total of 93 patients were eventually included in the study. Ages of the patients ranged from 22 to 87 years, with an average of 58.4 years, including 40 females and 53 males. In this study, the numbers of samples classified as tumor node metastasis (TNM) stages I+II and III+IV were 45 and 48, respectively. There were 81 patients with low grade tumors and 12 patients with high grade tumors. The number of patients with lymph node positive rectal cancer was approximately equal to that of patients with lymph node negative rectal cancer. Detailed demographic information on the patients and their clinicopathological features are listed in Table 1 .
Analysis of SATB1 mRNA expression in cancerous and normal rectal samples using qRT-PCR SATB1 mRNA was found to be expressed in both normal rectal tissue and rectal cancer specimens, but the general level of SATB1 mRNA expression in rectal cancer tissues was statistically significantly higher than that in normal mucosa (P=0.043). Among the 93 rectal cancer RNA samples tested, 45 cases showed overexpression of SATB1. Major differences in the overexpression of SATB1 in rectal cancer were observed. SATB1 mRNA expression in 22 tumors were less than 5-fold higher, two tumors were 5-to 10-fold higher, three tumors were 10-20 times higher, and 18 tumors were more than 20-fold higher than in normal rectal tissue.
Associations between SATB1 mRNA expression and clinicopathological features
The associations between clinicopathological features and SATB1 expression in individuals with rectal cancer are summarized in Table 1 . A higher prevalence of overexpressed SATB1 mRNA was found in tumors of patients with earlier onset of rectal cancer than in those diagnosed later in 392) . Furthermore, the expression of SATB1 protein tended to be increased in patients with mucinous adenocarcinoma or positive lymph node and no statistical significance reached, although the P values were extremely close to 0.05 (P=0.065 and P=0.074, respectively) ( Table 2 ).
SATB1 expression in human colon carcinoma cell lines
All of the five human colon cancer cell lines tested were also SATB1-positive at the mRNA level. Furthermore, the expressions of SATB1 gene in the colon cell line KM12C and its metastatic counterparts (KM12SM and KM12L4A) were significantly higher than those in the HCT116 and SW480 cells (P=0.001). Strikingly, the highly metastatic KM12SM and KM12L4A cell lines displayed higher levels of SATB1 expression compared with the poorly metastatic KM12C cell line (P=0.001). The amplification curves and corresponding C t values of SATB1 and β-actin gene in the colon carcinoma cell lines are shown in Fig. S1 . Moreover, the SATB1 mRNA and protein expressions were concordant (Fig. 2) .
Discussion
SATB1 is a tissue-specific MAR-binding protein that participates in chromatin higher structure packaging and tissue-specific gene expression [16] . The function of SATB1 was mainly studied in immune cells in the past decade, and it is known to play a vital role in the development and maturation of T cells [3] . SATB1 can regulate T cell gene expression by linking far distal target sequences in a cage-like network and recruiting transcription and chromatin-remodeling factors to the target genes [3, 6, 17, 18] . These findings would normally relegate SATB1 as a protein of interest primarily for molecular biologists, were it not for the recent revelation by Han et al. [7] that SATB1 is aberrantly expressed in human metastatic breast cancer and likely functions to reprogram chromatin organization and transcriptional profiles of breast tumors to promote growth and metastasis. That study revealed a previously unknown involvement of SATB1 in cancer development. Therefore, the role of SATB1 in breast cancer represents a new paradigm for understanding the mechanisms of other tumor and raises the possibility that it may participate in the development and progression of other malignant tumors. Subsequent studies also confirmed that elevated expressions of SATB1 in laryngeal squamous cell carcinoma and gastric cancer are significantly involved in both tumor invasion and metastasis [8] [9] [10] . Unfortunately, no study has reported to date on the relationship between SATB1 and colorectal carcinoma. The present study provided new insights into the role of SATB1 in the progression of rectal cancer. We found that high levels of SATB1 expression were closely correlated with invasive depth and TNM stage of rectal cancer, and the overexpression of SATB1 mRNA was more predominant in patients with earlier onset of rectal cancer. Our results also indicated that SATB1 expression tended to increase although not significantly in patients with mucinous adenocarcinoma or positive lymph node. To confirm these observations, we analyzed SATB1 expression in five colon cancer cell lines and found that all of them were also SATB1 positive at the mRNA and protein levels. Additionally, the SATB1 gene expressions in KM12C cells and their metastatic derivatives were significantly higher compared with the HCT116 and SW480 cells. We also found that the highly metastatic KM12SM and KM12L4A cell lines displayed higher levels of SATB1 compared with the poorly metastatic KM12C cell line. All these results indicated that the elevated expression of SATB1 may be a key genetic change that plays an important role in the progression of human rectal cancer.
Genetic alterations have been studied extensively during various stages of CRC progression. Therefore, it is critical to identify the altered the genes that accumulate during cancer progression, as well as those genes responsible for the acquisition of invasive and/or metastatic potential in cancer cells [19] . SATB1 was identified by Han et al. [7] as the first protein to facilitate tumor growth and metastasis by universally remodeling the chromatin structure and transcriptional expression of many genes. Thus, SATB1 was suggested to repress the activity of genes found near its DNA binding sites. However, some of the genes repressed by SATB1 are known to be up-regulated by Wnt signals. In 2008, Purbey and colleagues [20] reported that the transcriptional targets of SATB1 and CtBP1 overlap, suggesting common mechanism(s) of regulation and that the involvement of SATB1 acetylation in Wnt/β-catenin signaling in T cells. Most recently, Notani et al. [21] further established that SATB1 is involved in Th2 cell differentiation and functions downstream of the Wnt/β-catenin signaling pathway. Because activating mutations in the Wnt/β-catenin signaling pathway are associated with approximately 90% of CRC [22] and β-catenin, the major nuclear component of Wnt/β-catenin signaling, is directly regulated by SATB1 in breast cancer and T cells, it is imperative to identify whether (and how) SATB1 and Wnt/ β-catenin signaling might interact in CRC in future studies. If this potential interaction is proven to be functionally significant, new drugs targeting this molecular marker and therapeutic strategies can be developed accordingly.
Conclusion
In summary, our study presents the first link between SATB1 expression and rectal cancer development. Our results also have significance implications for exploring a new pathway in the progression of rectal cancer. Understanding more about the role of the SATB1 gene in patients with CRC may not only help clinicians to better determine the prognosis of patients but also guide the development of agents for the treatment of advanced or metastatic CRC.
